Compare GE Vernova Inc (GEV) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? GE Vernova Inc trades at $911.98 (market cap $250.83B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: GE Vernova Inc is far larger — about 29.6× Hinge Health Inc. Class A Common Stock's market cap, and GE Vernova Inc pays a 0.21% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 37 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GEV | HNGE | |
|---|---|---|
Market Cap | $250.83B | $8.47B |
Volume | 3,491,026 | 1,624,526 |
Sector | Industrials | Health |
52-Week High | $1.17K | $105.14 |
52-Week Low | $547.96 | $31.17 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $240.50B | $8.09B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,004.04, up 0.73% with strong bullish momentum from technical indicators and positive analyst sentiment. The stock shows impressive fundamental performance with 2026 revenue projected at $41.4B and net income of $9.5B, representing a 23.03% profit margin. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and strong backlog growth to $176B, positioning the company to benefit from AI-driven power demand.
The outlook remains positive with 76% analyst buy ratings and a $1,270 consensus price target suggesting 26% upside potential. Key risks include valuation concerns with P/E of 28.79 and EV/EBITDA of 85.64 appearing elevated, along with execution challenges in the wind power segment. The stock's strong cash flow generation and positioning in the AI power infrastructure theme support continued growth prospects despite rich valuations.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
